8-K: Apyx Medical Reports Strong Preliminary Q4, Full Year 2025 Revenue

Apyx Medical Corporation announced preliminary, unaudited revenue results for Q4 and full year 2025, showing significant growth in Surgical Aesthetics driven by the AYON launch.

Summary

• Total revenue for the fourth quarter of 2025 is expected to be in the range of approximately $19.0 million to $19.2 million, representing an increase of approximately 34% year-over-year.
• Surgical Aesthetics revenue for Q4 2025 is expected to be approximately $16.6 million to $16.8 million, an increase of about 38% year-over-year, including a 51% increase in the U.S. following the AYON launch.
• OEM revenue for Q4 2025 is expected to be approximately $2.4 million, an increase of about 13% year-over-year.
• Total revenue for the full year 2025 is expected to be in the range of approximately $52.7 million to $52.9 million, representing an increase of approximately 10% year-over-year.
• Surgical Aesthetics revenue for the full year 2025 is expected to be approximately $45.2 million to $45.4 million, an increase of about 17% year-over-year.
• OEM revenue for the full year 2025 is expected to be approximately $7.5 million, representing a decrease of 21% year-over-year.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary revenue growth for both the fourth quarter and full year 2025, particularly in the Surgical Aesthetics segment, driven by a successful new product launch. While OEM revenue saw a full-year decline, the overall financial performance and positive market commentary indicate a strong positive sentiment.

Positives

• Strong preliminary total revenue growth of approximately 34% year-over-year for Q4 2025.
• Significant preliminary Surgical Aesthetics revenue growth of approximately 38% year-over-year for Q4 2025.
• U.S. Surgical Aesthetics revenue increased approximately 51% in Q4 2025, demonstrating immediate momentum from the AYON commercial launch.
• Preliminary full year 2025 total revenue increased approximately 10% year-over-year.
• Preliminary full year 2025 Surgical Aesthetics revenue increased approximately 17% year-over-year.
• The company is well-positioned to capitalize on the expected increase in aesthetic surgical procedures in the U.S., partly fueled by GLP-1 therapies leading to patient weight loss and subsequent demand for skin tightening procedures.

Negatives

• Preliminary OEM revenue for the full year 2025 is expected to decrease by 21% year-over-year, to approximately $7.5 million.

Risks

• The preliminary revenue results are unaudited and subject to completion of year-end financial closing and audit procedures, meaning actual results could differ.
• Ability to gain requisite regulatory approvals for products from the FDA and other governmental and regulatory bodies, both domestically and internationally.
• Sudden or extreme volatility in commodity prices and availability, including supply chain disruptions.
• Changes in general economic, business, or demographic conditions or trends.
• Changes in and effects of the geopolitical environment.
• Liabilities and costs which may be incurred from pending or threatened litigations, claims, disputes, or investigations.

Future Outlook

Preliminary revenue results for the fourth quarter and full year ended December 31, 2025, are subject to completion of the company's year-end financial closing procedures and year-end audit procedures. The company plans to release its full fourth quarter and full year 2025 financial results in March 2026.

Management Comments

• "We are excited by AYONs commercial launch, which delivered immediate momentum and contributed to a strong fourth quarter, including an increase of approximately 51% in revenue for our Surgical Aesthetics segment in the U.S.", said Charlie Goodwin, President and CEO of Apyx Medical Corporation.
• "With Renuvion and AYON now in the market, we are well-positioned to capitalize on the expected increase in aesthetic surgical procedures in the U.S."
• "This positive industry momentum is being fueled, in part, by the adoption of GLP-1 therapies resulting in significant patient weight loss and loose and lax skin."

Industry Context

The company operates in the surgical aesthetics market, which is experiencing positive momentum. This trend is partly driven by the increasing adoption of GLP-1 therapies, which lead to significant patient weight loss and subsequent demand for procedures addressing loose and lax skin. The company's new AYON Body Contouring System and established Renuvion product position it to capitalize on this growing market.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong preliminary revenue growth and successful product launch, potentially leading to increased share value.
• Customers (surgeons and patients): Benefit from the availability of innovative products like the AYON Body Contouring System and Renuvion for advanced aesthetic procedures.
• Employees: Potential positive impact from company growth and product success, possibly leading to job security or expansion opportunities.

Next Steps

• Release of full fourth quarter and full year 2025 financial results in March 2026.

Key Dates

Keywords

Surgical Aesthetics, Apyx Medical, Renuvion, AYON Body Contouring System, Medical Devices, Revenue, Preliminary Results, Body Contouring, Helium Plasma Technology, FDA